ATE251886T1 - Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit - Google Patents

Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit

Info

Publication number
ATE251886T1
ATE251886T1 AT94925756T AT94925756T ATE251886T1 AT E251886 T1 ATE251886 T1 AT E251886T1 AT 94925756 T AT94925756 T AT 94925756T AT 94925756 T AT94925756 T AT 94925756T AT E251886 T1 ATE251886 T1 AT E251886T1
Authority
AT
Austria
Prior art keywords
apoe
map2c
disease
subject
binding
Prior art date
Application number
AT94925756T
Other languages
English (en)
Inventor
Warren J Strittmatter
Allen D Roses
Michel Goedert
Karl H Weisgraber
Ann M Saunders
Donald E Schmechel
Original Assignee
Univ Duke
Univ California
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Univ California, Medical Res Council filed Critical Univ Duke
Application granted granted Critical
Publication of ATE251886T1 publication Critical patent/ATE251886T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
AT94925756T 1993-08-31 1994-08-05 Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit ATE251886T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11491093A 1993-08-31 1993-08-31
PCT/US1994/008881 WO1995006456A1 (en) 1993-08-31 1994-08-05 METHODS AND COMPOSITIONS FOR BINDING TAU AND MAP2c PROTEINS

Publications (1)

Publication Number Publication Date
ATE251886T1 true ATE251886T1 (de) 2003-11-15

Family

ID=22358180

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94925756T ATE251886T1 (de) 1993-08-31 1994-08-05 Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit

Country Status (6)

Country Link
EP (1) EP0716591B1 (de)
AT (1) ATE251886T1 (de)
AU (1) AU681434B2 (de)
CA (1) CA2170727A1 (de)
DE (1) DE69433243T2 (de)
WO (1) WO1995006456A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414624D0 (en) * 1994-07-20 1994-09-07 Smithkline Beecham Plc Novel method
US5767337A (en) * 1995-07-31 1998-06-16 Duke University Creation of human apolipoprotein E isoform specific transgenic mice in apolipoprotein deficient "knockout" mice
US7964598B2 (en) 1995-10-17 2011-06-21 The J. David Gladstone Institutes ApoE4 domain interaction inhibitors and methods of use thereof
WO1997016194A1 (en) * 1995-11-02 1997-05-09 Warner-Lambert Company Naphthylazo inhibition of amyloidosis
US6313089B1 (en) 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
US7205280B2 (en) 1998-03-11 2007-04-17 Cognosci, Inc. Methods of suppressing microglial activation
US20030077641A1 (en) 1998-03-11 2003-04-24 Laskowitz Daniel T. Methods of suppressing microglial activation and systemic inflammatory responses
US6046381A (en) * 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
JP2002530122A (ja) * 1998-11-25 2002-09-17 サイオス インコーポレイテッド アミロイド関連疾患の予防及び治療
US6017913A (en) * 1999-05-03 2000-01-25 Warner-Lambert Company Naphthylazo inhibition of amyloidosis
WO2001056579A1 (en) * 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US8034762B2 (en) 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
WO2006029028A2 (en) 2004-09-02 2006-03-16 Cognosci, Inc. Improved apo e analogs and methods for their use
CN109942714B (zh) * 2019-04-02 2022-07-08 中国药科大学 一种功能多肽及应用

Also Published As

Publication number Publication date
EP0716591A1 (de) 1996-06-19
DE69433243D1 (de) 2003-11-20
CA2170727A1 (en) 1995-03-09
AU7556194A (en) 1995-03-22
AU681434B2 (en) 1997-08-28
EP0716591B1 (de) 2003-10-15
WO1995006456A1 (en) 1995-03-09
DE69433243T2 (de) 2004-07-29
EP0716591A4 (de) 1998-02-04

Similar Documents

Publication Publication Date Title
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
ATE347910T1 (de) Zusammensetzungen zur behandlung von ischamischem gewebe
ATE284959T1 (de) Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
DE69027865T2 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
DE69934967D1 (de) Verfahren zur verminderung der immunogenität von proteinen
YU46097A (sh) Nova klasa estara i njihove farmaceutske smeše
EA200100502A1 (ru) СПОСОБЫ И КОМПОЗИЦИЯ ДЛЯ ВОССТАНОВЛЕНИЯ КОНФОРМАЦИОННОЙ СТАБИЛЬНОСТИ БЕЛКА СЕМЕЙСТВА p53
ATE526019T1 (de) Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
ATE202940T1 (de) Mittel und methoden zur behandlung von plaque- krankheiten
ATE224713T1 (de) Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression
FR2751986B1 (fr) Gene implique dans le cadasil, methode de diagnostic et application therapeutique
FI900808A0 (fi) Humant mannos bindande protein.
DE60025008D1 (de) Bestimmung von adrenomedullin-bindenden proteinen
ATE300052T1 (de) Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
ATE290315T1 (de) Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits
GB9422175D0 (en) Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
ATE368110T1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
DE3584775D1 (de) Zusammensetzung zur behandlung von an haemophilia-a-inhibitor leidenden kranken.
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties